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ABSTRACT
All over the world there has been a sudden increase in the number of international travels, mostly for 
touristic purposes. According to the World Tourism Organisation, the number of international journeys 
exceeded 1.323 billion in 2017 and it continues to grow. Of the growing number of travellers more and 
more are the elderly (> 65 years), this fact can be attributed to longer life expectancy and a better quality of 
life, especially in the developed countries. The article lists the main destinations chosen by senior tourists 
and their reasons for travel, it also discusses physiological changes in organs and systems affecting the 
elderly, which are the result of travelling across time zones and to areas with different environment. The 
article looks at various groups of patients affected by chronic diseases and examines health-related con-
sequences of travel, including the most common complications. The general health prevention measures, 
with emphasis on vaccinations and antimalarial chemoprophylaxis, have also been discussed. 
(Int Marit Health 2018; 69, 4: 285–296)
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INTRODUCTION
The number of travelling older adults (> 65 years) is 
increasing every year, in keeping with growing numbers 
of travellers at all ages. According to the World Tourism 
Organisation [1], the number of international tourist arrivals 
reached 1.323 billion in 2017 and continues to grow. It is 
widely known that the population worldwide is getting older. 
Indeed, 8.7% of the world population is 65 and above [2]. 
One of the reasons for this is that in high-income countries 
live expectancy has been steadily increasing for decades [3]. 
According to European Commission statistics, live expectan-
cy at birth in the European Union is estimated at 83.6 years 
for women and 78.2 for men [4]. In the study performed by 
Kontis et al. [3], projections show continued increases in 
longevity in 35 industrialised countries. The number of el-
derly travellers is constantly growing not only because of the 
increased live expectancy, but also due to the improvement 
of the quality of life and of medical technology, significantly 
higher income, relatively few obligations and a longer time 
spent in retirement [5–7]. Normal aging is associated with 
physiological changes affecting all systems, especially the 
cardiovascular, respiratory, gastrointestinal, dermal, renal, 
endocrine, and musculoskeletal [8]. Therefore, elderly peo-
ple are at an increased risk of negative effects associated 
with their underlying medical conditions and medications 
they receive [9]. Concomitantly, physiological changes put 
older travellers at a much higher risk of travel-associated in-
fections and complications compared with younger patients 
[10]. For this reason, the effects of aging and physiological 
changes associated with this process are particularly import-
ant while discussing travel-related diseases. As international 
travels have become increasingly available to larger groups 
of travellers, elderly individuals now represent an increasing 
proportion of patients with travel-associated diseases [11]. 
Furthermore, as the number of elderly travellers is constant-
ly growing, there may be an increase in the number of elderly 
patients who seek pre-travel counselling [10].
EPIDEMIOLOGY
It is estimated that 15–30% of the total number of 
international travellers are people aged 60 years or more 
[11]. According to European Commission statistics, 48.8% 
of European Union citizens aged 65 and over took part in 
international and domestic travels in 2015. The number 
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of elderly travellers differed between European countries 
and ranged between 83.7% in Denmark and only 11.0% in 
Bulgaria [12]. In the study performed by Gautret et al. [11], 
49.1% of tourists aged 60 years and over were from Europe, 
36.4% from North America and 6.7% from Asia. Destinations 
chosen by senior travellers are also important; travel to 
developing countries has become increasingly popular. In 
the study by Gautret et al. [11], 47.1% of elderly travellers 
have chosen Asia as their travel destination, 21.9% went 
to Africa, 16.5% to Latin America and only 7.7% to Europe 
and 2.4% to North America. In another study performed by 
Alon et al. [13], 53.1% of elderly travellers went to East Asia, 
30.3% to South America and 14.6% to Africa. In comparison, 
in the Swiss study [5] the main destination were the tropical 
countries in South America. The other important issues to 
consider are the travel mode and conditions. The majority of 
senior travellers opted for organised tours (61.4%); however, 
10.4% of them backpacked [13]. According to Jaeger et 
al. [5], 8.1% travelled on a low budget. Regardless of age, 
visiting South-East Asia and travel under basic conditions 
is associated with a higher risk of acquiring travel-related 
diseases [13]. What is more, there is a relationship between 
nationality and the travel destination choice. For elderly Eu-
ropean travellers security is the priority, for Americans — it is 
comfort, for Canadians — entertainment and for Japanese 
seniors — health and safety [6]. The median travel duration 
is generally shorter in the elderly compared to younger trav-
ellers [11]. The group of older patients complied better with 
malaria chemoprophylaxis and dietary restrictions. Drinking 
and eating habits were also different between younger and 
older tourists. Only 16.2% of elderly travellers ate food from 
street vendors, compared to 37.9% of the younger travellers. 
No more than 8% of elderly travellers admitted drinking tap 
water, while among the younger travellers the figures were 
35% [13]. In the study performed by Gautret et al. [11], the 
main reason for journey for 66.3% of 7034 travellers aged 
60 years and older was tourism. Other common reasons 
for travel in this group were: business (16.7%), missionary, 
volunteer, research or aid work (8.5%), and visiting friends 
and relatives (8.0%). In the study carried out by Jaeger et 
al. [5], the main reasons included: tourism (87%), visiting 
friends and relatives (7.3%), and business (3.1%). The most 
popular activities among senior travellers during their trips 
are: going on city tours, visiting historic places, eating out 
and shopping, while they are generally not interested in 
water sports, sunbathing, camping or hiking [6]. Some of 
the elderly travellers perceive retirement as an opportunity 
to travel without any pressure. They can spend more time 
at a given destination and get to know it better [7]. Contrary 
to other age groups, 48% of elderly people indicated health 
as one of the main reasons not to travel [14]. According to 
Sundling et al. [15], health was the main obstacle to railway 
travel only for patients with low functional ability, whereas 
older travellers with high functional ability put costs and 
poor punctuality as the main obstacle to travelling more 
often. On the other hand, some elderly people who used 
to travel a lot as part of their job perceive retirement as an 
opportunity to travel less [7].
AGE-RELATED PHYSIOLOGICAL CHANGES 
AND THEIR CONSEQUENCES 
CARDIOvASCULAR SYSTEM 
Age is the greatest risk factor for cardiovascular disease 
[16]. There is a general tendency for the cardiac output to 
decline and systolic hypertension is much more likely to 
occur in this group of patients. Another problem of geri-
atric patients is arteriosclerosis. Stiffening, fibrosis and 
incremental accumulation of phosphate and calcium occur 
during the aging process [8, 9]. Arteriosclerosis is the lead-
ing cause of coronary artery disease (CAD) [17], whereas 
age and hypertension are significant risk factors [8, 17]. 
Cardiovascular events are a  common cause of in-flight 
medical emergencies, with exacerbations in CAD being 
one of the main incidences. Some diseases, e.g. mild and 
treated appropriately stable chronic angina and stable heart 
failure or controlled systemic hypertension are not contra-
indications to flying. What is more, it is even possible to 
fly 1 week after uncomplicated myocardial infarction or 
5 days after uncomplicated percutaneous coronary interven-
tion. However, patients with severe heart failure (New York 
Heart Association IV) or those with unstable angina are not 
recommended to travel by air. Individuals with moderate 
to severe systolic pulmonary hypertension (higher than 
60) may need supplementary oxygen. Another important 
issue is venous thromboembolism. The hazard is higher 
in patients with pre-existing risk factors, e.g. older age, 
malignancy, obesity, recent surgeries, inherited or acquired 
thrombophilia, polycythaemia or oestrogen therapy [10, 18]. 
As pointed out by Lee et al. [10] patients at the highest risk 
of venous thromboembolism may benefit from well fitted 
medical compression stockings and subcutaneous enoxa-
parin administered before and 1 day after air travel if the 
journey lasts more than 3 hours. 
RESPIRATORY SYSTEM
Aging-related changes in the respiratory system, includ-
ing a  decrease in vital capacity, an increase in residual 
volume, a reduction amount of protective mucous, impaired 
cough reflex, insufficient production of Ig A may all have 
a negative effect on elderly travellers [8, 9]. According to 
Guatret et al. [11], 14.6% of travellers aged 60 and over 
had a  respiratory tract infection, ranked as the second 
most common complaint in this group of patients. Even 
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though elderly travellers present less frequently with upper 
respiratory tract infections, they are at a higher risk of de-
veloping lower respiratory tract infections, e.g. pneumonia 
and bronchitis. Therefore, preventive measures against 
respiratory infections are particularly important for older 
adults [11, 13]. Another problem is hypobaric hypoxemia 
induced by high altitude and a poorer ventilatory response 
to hypoxia compared with younger patients, which may lead 
to exacerbation of underlying pulmonary diseases [10, 19]. 
Lee et al. [10] suggest that for this reason geriatric patients 
with certain chronic (e.g. chronic obstructive pulmonary dis-
ease) or acute (e.g. pneumonia) medical problems should 
contact a clinician prior to travel to assess the risk of ex-
acerbation. It is also essential to contact the airline before 
travel in the event that supplemental oxygen is required. 
In addition, older age may be a risk factor for developing 
high-altitude illness. 
GASTROINTESTINAL SYSTEM
Changes in the gastrointestinal system occur with ad-
vancing age, but they are moderate and minimally impact 
function of organs in the elderly patients [9]. As pointed out 
by Grassi et al. [20], no digestive diseases are seen only in 
geriatric patients, but compared with younger persons the 
prevalence of functional disorders affecting gastrointestinal 
system is significantly higher in the elderly. Changes in the 
aging gastrointestinal tract include decreased saliva pro-
duction, generalized slowing of peristalsis, reduced pepsin, 
bicarbonate and pancreatic enzymes (lipase, chymotrypsin, 
amylase) secretions, decreased biodiversity and endan-
gered stability of the intestinal microbiota [8, 9, 21]. Some 
of these changes, like reduced gastric motility and a decline 
in bicarbonate and prostaglandin production, may raise 
the risk of adverse drug events. Slowed peristalsis in the 
small and large intestine put older people at a higher risk 
for constipation [9]. On the other hand, many of the elderly 
people have special risk factors for developing travellers’ 
diarrhoea, e.g. diabetes and taking histamine-blockers or 
proton pump inhibitors, resulting in a reduction of the host 
defence of gastric acidity [13, 22]. There is also a higher 
probability of developing complications of travellers’ diar-
rhoea in this group of patients [22].
IMMUNE SYSTEM
One of the most noticeable changes associated with the 
immune system ageing is thymic involution, which results 
in a decreased output of mature T cells. B cells immune re-
sponse is also impaired due to age related changes [5, 10]. 
As a result, the immunity conferred through vaccinations 
received in the past may become impaired, a response to 
more recently received vaccines may be decreased and the 
duration of immunity is generally shorter. Also noteworthy 
are the changes in cytokine production, including lower 
level of Th1 cytokines (IL-12 and IFN-G) and an increased 
production of Th2 cytokines (IL-10 and TGF-B) [23]. Due to 
the dysfunction of the immune system elderly patients are 
more susceptible to infections, e.g. cosmopolitan diseases 
like pneumonia as well as travel-associated illnesses, e.g. 
malaria [5, 24].
SKIN
Changes in the skin are the most visible signs of ageing. 
They are especially pronounced in the uncovered parts of 
the body: the face, neck, upper part of the chest, hands 
and forearms, and result in the alteration of people’s phys-
ical appearance [8, 9]. Apart from the aesthetic aspect, 
skin ageing may have a negative effect on skin function 
and therefore it is more than barely a cosmetic problem 
[9, 25]. The degenerative changes that occur with age in-
clude a decrease in the amount of collagen, elastin, con-
nective tissue and fat [9, 25, 26]. Clinical presentations of 
age-related skin degeneration may indeed be very serious 
and may even manifest as basal and squamous cell carci-
noma and malignant melanoma [25]. Due to a decrease in 
melanocytes, skin is easily damaged by exposure to the sun, 
and so elderly travellers become increasingly vulnerable to 
the UV light [9, 26]. Therefore, it is crucial for the elderly to 
remember about adequate skin protection, especially while 
travelling to sunny destinations. 
MUSCULOSKELETAL SYSTEM
Ageing is associated with natural changes in body com-
position. Fat mass increases while muscle mass and total 
body water decreases. These changes are responsible for 
reduce muscle strength and growing muscle fatigue in elder-
ly people [9, 27]. Another common problem of geriatric pa-
tients is osteoporosis, which may result in bone fractures [8]. 
All of that put elderly people at higher risk for falls, especially 
as travellers visit unfamiliar destinations [9, 10].
POLYPHARMACY 
Another problem of the elderly is polypharmacy due to 
multimorbidity, as one or more medications can be used 
to treat single disease [28]. Although polypharmacy is not 
consistently defined in the literature, it is usually explained 
as taking 5–6 medications daily [29]. As Masnoon et al. [28] 
pointed out, numerical only definition is the most popular, 
but even the numerical definitions vary to a large extent; 
some define polypharmacy as the use of two or more drugs 
concurrently while others as the use of above 11 medica-
tions at the same time. There are also other ways to explain 
polypharmacy, e.g. definitions which take into account both 
the number of medicines taken and also the length of ther-
apy or treatment setting, as well as descriptive definitions. 
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Differences in the understanding of the term ‘polypharmacy’ 
may be the reason why its prevalence varied a great deal 
between different studies. Kim et al. [29], in South Korea, 
reported that polypharmacy was found in 86.4% of elderly 
patients, whereas in the Finnish study performed by Jyrkkä 
et al. [30], polypharmacy was only seen in 33% of patients. It 
is important to note that the use of medications can impact 
morbidity and quality of life and taking multiple of drugs may 
have many negative consequences [31, 32]. Polypharmacy 
has been associated with increased risk of adverse drug 
events, medication non-adherence or drug-interactions [32]. 
According to Doan et al. [33], the risk of drug–drug inter-
actions increase with the number of medicaments taken: 
when a patient is taking 5–9 drugs daily, it is estimated at 
50%, and in patients taking 20 or more medications, the 
risk increases to 100%. It is essential to remember about 
potential drug interactions that may occur during travel [22]. 
Drug–drug interactions between antibiotics used for em-
piric therapy of travellers’ diarrhoea, antimalarials used 
for chemoprophylaxis, altitude illness prevention drugs and 
other common medications prescribed to the elderly should 
be considered prior to travel [10, 22]. Another important 
issue is that many elderly travellers fail to take prescribed 
drugs, especially diuretics during travel [26], and leave their 
emergency or routine medications at home [19].
MOST COMMON TRAvEL-ASSOCIATED 
DISEASES 
ARTHROPOD-BORNE DISEASES 
Malaria is one of the most widespread infectious diseas-
es in the world. It is a mosquito-borne disease caused by five 
species of protozoa that belong to the Plasmodium genus: 
P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. 
According to the World Health Organisation (WHO), there 
were 216 million registered malaria cases and 445 thou-
sand deaths in 2016 [34]. In an observational study that 
analyse the trends in the prevalence of imported malaria in 
London [35], of a total of 15,473 cases reported between 
2000 and 2004, 5.9% were seen in patients older than 
60 years; between 2005 and 2009 the prevalence of malar-
ia in this group reached 7.7% and between 2010 and 2014 
— 8.7%. In the study performed by Allen et al. [36], 5.9% of 
the cases reported between 2002 and 2012 were found 
in patients aged 65 years or older. Travellers coming from 
non-endemic countries visiting endemic regions are at a par-
ticularly high risk for malaria acquisition, the mortality rates 
associated with malaria are also higher in this group of trav-
ellers [37]. What is more, because of physiological changes 
and multimorbidity elderly travellers are at an increased risk 
of serious complications of malaria and other travel-related 
diseases [36]. A questionnaire-based survey carried out at 
Amsterdam Airport Schiphol showed that travellers aged 
60 and over are at a  similar risk of malaria as younger 
persons [38]; however according to Checkley et al. [39], 
patients over the age of 65 are approximately 10 times 
more likely to die from malaria in comparison with young-
er patients. Also, Allen et al. [36] found that the length of 
hospital stay (LOS) increases with age — the median LOS 
was 8 days for the elderly compared to a median LOS of 
3 days in younger groups. While the median time from 
consultation to diagnosis was 2 days and ranged between 
0 and 35 days resulting in a delay of treatment initiation. It 
is essential to note that age, delayed diagnosis and a delay 
in treatment initiation are significant risk factors for fatal 
malaria. Therefore it is important to take patient’s history 
very carefully, especially if a  returned traveller presents 
with fever — this can facilitate early diagnosis, improve 
clinical outcomes and decrease morbidity and mortality. 
However, due to multiple comorbidities presenting features 
vary with age, so the identification of imported infection may 
be challenging [36].
Dengue is a disease caused by any one of the four re-
lated viruses and is transmitted by mosquitoes. According 
to the WHO [40], 390 million dengue infections occur every 
year. Dengue virus causes a wide variety of diseases from 
a self-limiting febrile illness — dengue fever to a severe, 
life-threatening diseases known as dengue haemorrhagic 
fever (DHF) or dengue shock syndrome (DSS). DHF and 
DSS usually affect children living in endemic areas and 
infrequently adults, especially travellers [41]. In the study 
performed by Rowe et al. [42], 4.4% of the 6989 cases were 
found in patients aged 60 or older, although in other studies 
the prevalence of dengue in patients older than 65 years 
ranged between 4.2% and 8.7% [43, 44]. Although the 
number of cases in the elderly is relatively low, a Taiwanese 
study showed that 69.9% of all patients hospitalised for 
dengue and 85.3% of dengue patients admitted to inten-
sive care units were over 60 [45]. Compared with younger 
patients, the classical symptoms including a  headache, 
rash, pain are less common in the elderly. Despite this 
fact, the time from consultation to dengue diagnosis was 
similar in the two groups. It is important to mention that 
that elderly stayed in hospital longer (5 vs. 4 days) [42]. 
Another example of an arthropod-borne illness is Chagas 
disease (CD). It is most commonly transmitted to humans 
by triatomine bugs and is caused by the Trypanosoma 
cruzi parasite. It is estimated that eight million people are 
infected, particularly in Latin America; however, more than 
300,000 people with T. cruzi infection live in the United 
States [46]. In the study performed by Pereira et al. [47], 
of the total number of 411 patients 23.6% were older than 
60 years and between 2005 and 2013 the prevalence of 
CD in the elderly was steadily increasing. In this group of 
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patients the cardiac form of CD was predominant, followed 
by the mixed and digestive forms [47, 48]. The elderly af-
fected by CD show a greater number of ageing-associated 
diseases. What is more, the clinical interaction between 
CD and other age-related illnesses may increase mortality 
and morbidity and may reduce the quality of life. Indeed, 
morbidity rates among the elderly are higher in compar-
ison with other age groups [47–49]. Pereira et al. [49] 
highlighted that the elderly patients with CD need special 
attention from healthcare providers and that further studies 
in this group of patients are necessary. Leishmaniasis is 
a disease caused by an infection with Leishmania parasites 
and is spread by the bite of phlebotomine sand flies. There 
are three clinical forms of leishmaniasis: visceral (VL), 
cutaneous and mucocutaneous. Leishmaniasis is found 
in the tropics, subtropics and southern Europe. However, 
90% of VL cases (the most severe form of leishmaniasis) 
are reported from several countries only; these countries 
however are popular travel destinations, e.g. Brazil, India 
or Nepal [23, 50, 51]. According to Montalvo et al. [52] 
high human global mobility is one of the factors which have 
led to an increase in the number of cases in non-endemic 
regions such as Cuba. Also noteworthy is that lethality rates 
for VL have risen in many areas over the past 10 years, 
especially in patients over 50 years. A higher lethality is 
connected with late diagnosis, atypical presentations and 
multimorbidity. Despite the fact that multidrug therapy is 
associated with higher risk of drug interactions and cumu-
lative toxicity, it was not found to influence the mortality 
rate in VL patients [23].
TRAvELLERS’ DIARRHOEA
Travellers’ diarrhoea (TD) is the most common trav-
el-related health problem which affects 20–50% of in-
ternational travellers [53]. It is defined as three or more 
loose stools occurring within 24 hours associated with 
one or more enteric symptom. TD is most common among 
people travelling to South-East Asia, Sub-Saharan Africa 
and Latin America. Bacterial infections cause 50–80% of 
TD cases. Traditionally, enterotoxigenic Escherichia coli 
is considered to be the major causative pathogen of TD. 
Other etiological factors include enteroaggregative E.coli, 
enteropathogenic E.coli, Shigella, Salmonella, and espe-
cially in South-East Asia — Campylobacter. Less common 
are viral and protozoal pathogens [53, 54]. TD is usually 
a  mild, self-limiting disease, and it generally resolves 
spontaneously after 3–4 days. However, it may be the 
cause of activity limitation leading to loss of business or 
vacation days. In some cases the clinical picture of TD 
can be more severe — about 10% of travellers affected 
by TD seek medical care and hospitalisation is required 
in up to 3% of cases [54]. Acute TD was shown to be less 
frequent in the elderly compared to younger travellers 
[11]; however, it is important to highlight that some group 
of elderly patients are at a higher risk of TD sequelae. For 
example, travellers with age-associated diseases, e.g. 
heart failure or renal insufficiency are more vulnerable 
to dehydration and electrolyte imbalance, which can lead 
to the exacerbation of the underlying disease. TD can 
also lead to persistent gastrointestinal symptoms like 
post-infectious irritable bowel syndrome (PI-IBS) or other 
post-infectious sequelae like Guillain-Barre syndrome or 
reactive arthritis. Generally, older travellers are at lower 
risk of PI-IBS in comparison to the younger ones; never-
theless, patients with severe disease are at an increased 
risk of PI-IBS. What is more, medicines commonly used for 
travellers’ diarrhoea, such as antibiotics and anti-motility 
agents, may impact TD’s potential to develop into PI-IBS 
[10, 54]. Guillain-Barre syndrome, typically associated 
with a Campylobacter infection, most commonly affects 
young adults and the elderly and may lead to permanent 
disability or even death [54]. 
HIGH-ALTITUDE ILLNESS 
In 2013, more than 100 million people travelled to areas 
where altitude illness is likely to occur. It is important to note 
that high-altitude cities, like Cusco, La Paz or Lhasa, are be-
coming popular tourist destinations also among elderly trav-
ellers and travellers with chronic illnesses [55]. There are 
three main forms of the disease: acute mountain sickness 
(AMS), high-altitude pulmonary oedema (HAPE) and high-al-
titude cerebral oedema (HACE). AMS is not life-threatening, 
although it may lead to more severe conditions: HAPE and 
HACE. Risk factors for developing high-altitude illness in-
clude quick ascent, previous history of AMS, HAPE or HACE, 
inadequate fluid intake and climbing up despite signs which 
may indicate poor tolerance of height [55, 56]. According 
to Gautret et al. [11], elderly people may be at higher risk 
of developing high-altitude illness. On the other hand, other 
studies showed that older travellers with no co-morbidities 
have no increased risk of the disease [55], although the 
risk of HAPE may be elevated in individuals over the age 
of 65 [56]. Contraindications to travel to areas located at 
high altitude include common age-related diseases such as 
severe obstructive pulmonary disease, symptomatic pulmo-
nary hypertension, severe or uncontrolled heart failure or 
severe ischaemic heart disease [55, 56]. The best way to 
avoid AMS is primary prevention, which include appropriate 
physical preparation, slow gradual ascent, pre-acclimatisa-
tion, adequate fluid intake and avoiding overexertion. In the 
case of patients with a history of altitude illness or travellers 
who are not able to follow the recommendations above 
medications may be a useful adjunct to the prevention of 
high-altitude illness [55–57].
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PREvENTION OF ELDERLY TRAvELLERS 
PRE-TRAvEL CONSULTATION 
Pre-travel counselling has become an essential part of 
comprehensive family medicine over the last years [58]. 
The aim of the pre-travel health consultation is to prepare 
travellers for a safe and healthy trip. A healthcare provider 
familiar with travel medicine should assess the risk of travel 
and provide proper guidance. These consultations give the 
opportunity not only to provide a patient with specific infor-
mation but also to administer all necessary vaccinations and 
prescribe medications for self-treatment of diarrhoea or for 
malaria chemoprophylaxis. The effectiveness of a pre-travel 
consultation depends both on expert advice and patient 
compliance [10, 58–60]. Elderly people, especially with 
comorbidities including cardiovascular disease or diabetes 
mellitus are at a higher risk of travel-associated diseases, 
therefore they require greater attention [59]. In the study 
performed by Gautret et al. [11], the proportion of patients 
who sought pre-travel advice was 42.2% among patients 
aged 60 and over, and 51.7% in travellers aged 18–45 
years. According to Jaeger et al. [5], almost 10% of patients 
who obtained pre-travel health advice were people aged 
60 or above. This group of patients consulted a travel clinic 
earlier compared to middle-aged adults. The most common 
reasons for not seeking pre-travel advice included: not being 
aware of such a necessity, the belief that prevention mea-
sures undertaken by a patient would be sufficient, financial 
limitations and language barriers [61].
NON TRAvEL-RELATED vACCINES
As mentioned before, a  pre-travel consultation gives 
an opportunity to administer routine vaccines. Immunisa-
tions are extremely important for older adults, due to their 
increased vulnerability to infections. Although, it must be 
remembered that immunogenicity and efficiency of most 
vaccines are decreased due to age-associated changes in 
the immune system and there are no alternative schedules 
to compensate for the immunosenescence for the major-
ity of vaccines [10, 62]. Routine influenza vaccination is 
particularly recommended in the elderly as they are highly 
vulnerable to influenza and are at a higher risk of developing 
serious complications from the disease. Approximately 90% 
of influenza-associated deaths occur among the elderly [63]. 
Influenza vaccination should be considered prior to travel to 
tropical and subtropical countries. According to Mutsch et 
al. [64], influenza is the most common vaccine-preventable 
infection in travellers to tropical or subtropical areas and 
immunisation should be recommended to the traditional risk 
groups, e.g. senior travellers and patients with multiple co-
morbidities. Several studies demonstrated clinical efficacy 
of influenza immunisation in the elderly, resulting in a re-
duced number of influenza-associated hospitalisations and 
deaths, although generally, seroprotection rates are lower in 
people age 65 and older [10, 62]. In some cases it may be 
reasonable to prescribe elderly travellers a self-treatment 
course of zanamivir or oseltamivir, in case the vaccine is 
ineffective [10]. Community-acquired pneumonia is another 
major health issue affecting the elderly globally; Strepto-
coccus pneumoniae being the leading cause of CAD. Most 
industrialised countries recommend routine vaccination 
to all adults age 65 and older. Both the 23-valent pneumo-
coccal polysaccharide vaccine (PPSV23) and the 13-valent 
pneumococcal conjugate vaccine (PCV13) are approved 
for the use [65, 66]. Systematic review and meta-analysis 
performed by Falkenhorst et al. [66] showed that PPSV23 
is indeed effective, although previous studies had demon-
strated its ineffectiveness. What is more, PPSV23 should 
be recommended for routine vaccination, due to its broader 
serotype coverage compared to PCV13. As pointed out by 
Lee et al. [10], there is not enough information regarding 
the prevalence of pneumococcal pneumonia in travellers; 
however, a pre-travel counselling visit is a good opportunity 
to ensure that elderly travellers are aware of the current 
vaccination recommendations. It is estimated that more 
than 90% of adults are latently infected with varicella zoster 
virus (VZV) and are at risk for herpes zoster. The primary 
infection is especially likely to occur in children; however, 
due to immunosuppression or immunosenescence viral 
reactivation may occur at any age and may develop into 
herpes zoster. The disease is most frequent in adults aged 
50 and over and nearly 50% of all cases affect individuals 
older than 85 years of age. Elderly people are also at a high-
er risk of developing complications from herpes zoster, such 
as postherpetic neuralgia. An attenuated live-vaccine has 
been licensed for use in adults above 50 years old and is 
recommended to all adults older than 60 in some coun-
tries. The vaccine reduced the incidence of herpes zoster 
by 51.3% and showed 66.5% efficacy against postherpetic 
neuralgia in patients; however, its overall efficacy decreased 
with age. It is important to remember that immunisation 
with live vaccines is contraindicated in immunosuppressed 
patients [62, 65, 67]. In the study performed by Lal et al. 
[67], the overall efficacy of a new adjuvanted herpes zoster 
subunit vaccine was 97.2%. Little is known about the herpes 
zoster prevalence among travellers; however, due to its high 
prevalence among the elderly it is possible that an outbreak 
may occur while travelling. It is reasonable to administer 
a full course of the vaccine to senior travellers, and if the 
last dose had been administered more than 8 years prior 
to travel, a booster dose is recommended [10]. Vaccination 
against tetanus, pertussis and diphtheria is advised to be 
given to all adults. In many countries patients are recom-
mended to receive a booster dose every 10 years; in some 
www.intmarhealth.pl 291
Marcin Woś, Krzysztof Korzeniewski, The older traveller
countries booster intervals are shortened for patients over 
the age of 65 as the response to the vaccination becomes 
impaired with age [62, 65]. As Lee et al. [10] pointed out, 
there is little information about the incidence of tetanus, 
diphtheria and pertussis in travellers. Due to the measles, 
mumps and rubella (MMR) outbreaks in the United States 
there has recently been a focus on immunization against 
MMR;, however, the MMR vaccine is not essential for the 
elderly travellers.  
TRAvEL-RELATED vACCINES
A  single dose of live-attenuated yellow fever vaccine 
provides lifelong immunity in the majority of patients. In the 
study performed by Jaeger et al. [5], it was the most often ad-
ministered vaccine in the group of elderly travellers. The vac-
cine is highly effective; however, in some groups of patients, 
e.g. individuals over 60 years old, the risk of developing 
a reaction to the immunisation may be elevated [68]. Side 
effects are rare, but can be severe, including yellow fever 
vaccine-associated viscerotropic disease (YEL-AVD) and yel-
low fever vaccine-associated neurologic disease (YEL-AND) 
which may manifest as meningoencephalitis, disseminated 
encephalomyelitis or Guillain-Barre syndrome [10]. The risk 
of YEL-AVD or YEL-AND is approximately 0.5/100,000 ad-
ministered doses. However, the risk of YEL-AVD in patients 
aged over 60 years is about 1.0–1.1/100,000 distributed 
doses, rising to 2.3–3.2/100,000 in individuals aged above 
70 [5]. Another study also showed that the risk of serious 
systemic adverse events was significantly higher in individ-
uals aged 65 years or older in comparison to the 25–44 
age group. Additionally, a majority of deaths from YEL-AVD 
were seen in adults aged 45 years and above [69]. Indeed, 
more travellers were found to have died from YEL-AVD than 
yellow fever itself [10]. It is the role of a healthcare provider, 
in collaboration with a patient, to decide whether the bene-
fits from vaccination outweigh the risks [10, 68]. Hepatitis 
A is the second most common vaccine-preventable disease 
among non-immune travellers [10] and international travel 
was identified to be the major risk factor for hepatitis A virus 
(HAV) acquisition [70]. The incidence rate varies between 
6.0 and 30.0 cases per 100,000 months of stay in virtually 
all developing countries [71]. In children a majority of infec-
tions are asymptomatic; however, in adults the infection 
often leads to acute hepatitis that may result in prolonged 
incapacitation or to acute liver failure [72]. In the study per-
formed by Mutsch et al. [71], 5.3% of all hepatitis A cases 
occurred in the group of patients older than 60 years. There 
are several effective hepatitis A vaccines with a very low risk 
of side effects [70]. However, due to their immunosenes-
cence, individuals over 50 years are recommended to re-
ceive two doses of the vaccine. The seroprotective rate was 
found to be 65% after the first dose and 97% after receiving 
the booster (in the group of patients aged 18 to 45 years it 
was 100% after a single dose) [10]. Hepatitis A vaccine is 
recommended to high risk groups, e.g. all people who travel 
to endemic areas or those who have chronic liver disease 
[70]. In the study performed by Jaeger et al. [5], travellers 
over the age of 60 received the vaccine significantly less 
often compared to younger groups. Hepatitis B is one of 
the most common vaccine-preventable travel-associated 
infectious diseases. It is estimated that approximately 240 
million people worldwide are infected with hepatitis B virus 
(HBV) and approximately 1 million people die each year 
from HBV-related illness [73]. The risk of acquiring HBV 
during the travel is relatively low (about 0.2 to 0.6 per 1000 
person-months). However, elderly people are more likely 
to acquire travel-associated HBV infection as they require 
medical treatment more often than younger travellers and 
because medical tourism is growing in popularity [74]. About 
20% of patients with hepatitis B infection need to be hospi-
talised and the risk is doubled in individuals 50 years and 
older. What is more, elderly patients with co-morbidities, 
such as liver or renal disease or diabetes are at a higher risk 
of developing complications from hepatitis B [75]. However, 
the risk of chronic HBV infection in people over 40 years 
of age is lower in comparison to young adults (6% vs. 8%) 
[76]. The hepatitis B vaccine is recommended to all unvac-
cinated travellers going to regions with intermediate to high 
prevalence of chronic hepatitis B; however, only 15–30% 
of international travellers had received a  full vaccination 
course prior to travel [73]. The Swiss study showed that 
hepatitis B vaccination was administered significantly less 
often to senior travellers [5]. It is important to note that age 
is the strongest predictor of vaccine response. In the study 
performed by Van Der Meeren et al. [75], vaccine protection 
rate was above 90% in individuals aged 20–49 years and 
only 64.8% in those aged 65 years or more. Another study 
showed that only 75% of the people vaccinated after the 
age of 60 years develop protective antibody levels [77]. 
For this reason, further studies are necessary to establish 
if elderly patients would benefit from additional or higher 
doses of the hepatitis B vaccine [75]. Typhoid is one of 
the most commonly diagnosed vaccine-preventable illness 
in returned international travellers. The incidence rate of 
typhoid infection is estimated at 1–10 cases per 100,000 
travellers to developing countries [78]. The effectiveness 
of typhoid vaccine has been reported to be 65% to 80% 
[79, 80] and no significant difference in efficiency by age 
group has been noticed [79]. According to Lee et al. [10], 
typhoid vaccine should be considered in elderly travellers 
to endemic regions as an effective way of preventing the 
disease. Rabies is a preventable fatal disease that causes 
50,000–55,000 deaths worldwide each year. However, in 
the decade prior to the study performed by Gautret et al. [81] 
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only 22 cases have been confirmed in travellers. Many 
studies confirmed safety and immunogenicity of the rabies 
vaccine with the overall seroconversion rate being 94.5% 
in patients up to age 65 [81, 82]. WHO recommends the 
rabies vaccine to all travellers [10]. Other travel-related vac-
cines include meningococcal, polio or Japanese encephalitis 
vaccines. The conjugated meningococcal vaccine needs to 
be considered in all senior travellers. Moreover, in some 
settings, e.g. the Hajj pilgrimage, the vaccine is compulsory 
for all pilgrims. The polio vaccine should also be considered 
in this group of patients and may be a requirement for trav-
ellers going to endemic areas. The Japanese encephalitis 
vaccine should be given to senior patients that travel to 
endemic regions [10]. 
MALARIA PREvENTION
Travellers to malaria-endemic regions should be in-
formed about the effective methods of protection against 
insect bites (e.g. covering arms and legs, using insect re-
pellents, e.g. DEET, and permethrin impregnation) [83]. 
Returned travellers who develop a febrile illness are recom-
mended to seek prompt medical assistance. The recommen-
dations concerning malaria prophylaxis refer to all travellers, 
regardless of age [10]. Yet, a study carried out by Alon et 
al. [13] revealed that travellers over the age of 60 used 
insect repellents significantly less often than travellers aged 
20–30 years (46.6% vs. 60%). Chemoprophylaxis is likewise 
essential to prevent malaria and when taken properly, it is 
highly effective. Main options for malaria chemoprophylaxis 
include atovaquone/proguanil, doxycycline, mefloquine and 
chloroquine. It should be offered to all patients travelling to 
endemic areas, when an exposure to malaria is time-limited 
and acceptable compliance is realistic. All of these drugs 
are well tolerated by older patients; however, it is important 
to remember about possible side effects, contraindications 
and drug–drug interactions [10, 83]. Atovaquone/proguanil 
is the most frequently prescribed chemoprophylactic agent 
in the group of elderly travellers [13]. It has very few drug– 
–drug interactions which is particularly important consider-
ing the fact that polypharmacy is increasingly common in 
elderly patients. However, travel medicine providers should 
be aware of potential interactions between atovaquone/
proguanil and metoclopramide or warfarin. Possible side ef-
fects may include headache and abdominal pain, yet, these 
are very rare. There are not pharmacokinetics differences 
between elderly and younger patients and dosing regimens 
do not need to be modified, regardless of age. However, 
the drug cannot be used in patients with severe renal in-
sufficiency (creatinine clearance < 30 mL/min) [10, 84]. 
Doxycycline may be used in the elderly for the prevention of 
malaria; however, it is associated with many inconvenient 
side effects, including oesophageal irritation, ulceration 
or photodermatitis. What is more, dietary and supplement 
restrictions may be necessary while taking doxycycline. It is 
also important to remember about drug–drug interactions 
between doxycycline and calcium salts, carbamazepine, 
phenytoin or warfarin. Another drug commonly used for 
the prevention of malaria is chloroquine, although due to 
high Plasmodium resistance to the drug, it has been used 
in limited settings. Moreover, long-term use of chloroquine 
is associated with retinopathy and macular degeneration. 
Interactions with amiodarone, sotalol, propranolol, metop-
rolol, carvedilol, fluoxetine, paroxetine, ciprofloxacin, levo-
floxacin, azithromycin or digoxin are likely to occur, and 
therefore, the drug is not recommended to the elderly [10, 
83]. Mefloquine is more often recommended to younger 
travellers [13], especially those who travel to endemic ar-
eas for a longer period of time [83]. According to Lee et al. 
[10], it should not be used in elderly patients with cardiac 
conduction disease or neuropsychiatric disorders. However, 
as Hahn et al. [83] pointed out, the risk of neuropsychiatric 
side effects is in general overstated. Nevertheless, there 
are many drug–drug interactions between mefloquine and 
carbamazepine, phenytoin, citalopram, fluoxetine, azithro-
mycin, verapamil, carvedilol or warfarin [10]. Main reasons 
for declining to take chemoprophylaxis include cost, lack of 
awareness and scepticism about therapy efficiency, inap-
propriate assessment of personal risk or failure to access 
drugs before travel [35]. It is essential to highlight that 
patients whose main reason to travel is visiting friends and 
relatives are less likely to take antimalarial prophylaxis [85].
Chemoprophylaxis is effective only with appropriate patient 
compliance [83]. In the study performed by Hill [86], 80% 
of travellers stated that they were fully compliant with their 
chemoprophylaxis regimen. Non-compliance affects all age 
groups; however, elderly patients generally comply better 
with the prescribed drug regimen According to Alon et al. 
[13], 60.7% of individuals at the age of 60 and above were 
completely compliant compared to 33.8% travellers aged 
20–30 years. The main reason for not complying with rec-
ommended regimen in the group of elderly travellers was 
the statement that “nobody takes these drugs anyway” 
(19.6%). For 7.1% of the elderly the main reasons included 
possible side effects, 6.2% of senior travellers stated that 
did not believe in effectiveness of the drugs and finally, for 
2.6% of them the regimen was too inconvenient. 
TRAvELLERS’ DIARRHOEA PREvENTION  
AND EARLY SELF-TREATMENT
Options for preventing travellers’ diarrhoea, in travellers 
of all ages, include avoidance of unsafe food and drinks, 
frequent hand washing, vaccination, non-antibiotic and an-
tibiotic interventions. As mentioned before, senior travellers 
tend to comply with travel health precautions better than 
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the younger ones [13, 53, 54]. The orally administered, 
killed whole-cell cholera vaccine has more than 90% ef-
ficiency against Vibrio cholerae and due to the antigenic 
similarity it may also reduce enterotoxigenic Escherichia coli 
TD. Effectiveness of probiotics in preventing TD is limited. 
Bismuth subsalicylate can provide up to 65% protection 
against TD; however, it is important to remember about 
potential drug–drug interactions, especially in elderly trav-
ellers. It may also reduce the absorption of doxycycline, 
used for malaria chemoprophylaxis. Frequent administra-
tion of bismuth subsalicylate may lead to decrease in the 
overall compliance [54]. Antibiotics are up to 90% effective 
in preventing TD. Antibiotic options for prevention of TD 
include fluoroquinolones (levofloxacin and ciprofloxacin), 
rifaximin and azithromycin. Despite high efficiency, anti-
biotic prophylaxis has a number of disadvantages which 
limit its usefulness, especially among elderly travellers. 
The disadvantages include possible side effects, cost, drug 
interactions, the risk of acquiring Clostridium difficile in-
fection or antibiotic resistant microorganisms [53, 54, 87]. 
Rifaximin use is usually limited by cost. Azithromycin and 
levofloxacin (but not ciprofloxacin) increase the risk of ven-
tricular arrhythmia and cardiovascular death and may lead 
to electrolyte imbalance in cases of severe diarrhoea. In 
light of the data, the above-mentioned antibiotics should 
be avoided in patients with QTc prolongation and are not 
recommended to patients with underlying heart disease 
[54]. What is more, azithromycin and fluoroquinolones may 
interact with many other drugs, e.g. citalopram, fluoxetine, 
escitalopram, amiodarone, dronaderone, atorvastatin, sim-
vastatin, warfarin and multivitamins or minerals [10]. In 
general, antibiotic dosage regimens need to be suitably 
modified for use in the elderly [87]. Initial symptoms of TD 
should be an indication to self-treatment based on oral 
rehydration therapy, this is particularly important for the 
elderly. Although in general increasing the amount of fluid 
with clean water is enough, WHO-formulated oral rehydra-
tion salts are recommended, especially for moderate and 
severe dehydration and in vulnerable groups of patients, 
i.e., older travellers. In mild cases of nondysenteric TD, 
antimotility agents such as loperamide can be used. If 
TD is moderate or severe, symptoms worsen or do not 
subside after 24 hours of loperamide usage, a combined 
therapy with loperamide and antibiotics is needed. Anti-
biotics for early self-treatment are generally the same as 
these used for TD prevention [53, 54]. Patients should 
seek medical assistance if symptoms persist or worsen 
despite self-treatment, if TD is accompanied by persistent 
fever, chills, bloody diarrhoea, abdominal pain, intracta-
ble vomiting, or if accurate oral rehydration therapy is 
impossible. Senior patients with underlying diseases who 
develop TD are recommended to look for medical care 
earlier than other patients, due to increased risk of severe 
and complicated TD [54]. Antibiotic prophylaxis should be 
reserved for high risk travellers, e.g. immunocompromised 
patients [54]. While antibiotic treatment of TD in elderly 
travellers should only be limited to severe cases. There 
are several reasons for these recommendations. Firstly, 
senior travellers are at higher risk of extended spectrum 
beta-lactamase (ESBL) carriage and colonisation with other 
multi-drug resistant bacteria. ESBL carriage may, in turn, 
lead to complications such as the urinary tract infections 
or prostatitis [10]. What is more, although antibiotics and 
anti-motility agents are effective in the treatment of TD, 
their application may increase the risk of developing PI-IBS 
[54]. Antibiotic use during travel has also been associated 
with increased risk for C. difficile infection [88]. In light of 
these findings, antibiotic options may only be used for the 
treatment of TD when it is absolutely necessary. 
ALTITUDE SICKNESS PREvENTION 
The most commonly prescribed drug to prevent AMS is 
acetazolamide. It decreases the metabolic alkalosis, acts 
as a mild diuretic thus reducing oedema and it is the only 
one drug available which facilitates acclimatisation. Acet-
azolamide should be used the night before planned ascent 
until the beginning of descent or until a person has been 
at the target elevation for 2–3 days. The effectiveness of 
acetazolamide 250 mg daily in decreasing AMS has been 
demonstrated; however, it is important to remember about 
contraindications and drug interactions, especially in the 
group of elderly travellers [55, 89]. The study performed by 
Alon et al. [13] demonstrated that elderly travellers used ac-
etazolamide for high-altitude illness prevention significantly 
more often than younger travellers (58% vs. 8.3%). Aller-
gies, previous anaphylactic reactions, significant hepatic 
and renal dysfunction, severe chronic lung dysfunction are 
contraindications to acetazolamide. As mentioned before, 
common problem of elderly patients is polypharmacy and 
as a  consequence drug–drug interactions. For example, 
patients on high-dose acetylsalicylic acid (325 mg daily) are 
at higher risk of metabolic acidosis while using acetazol-
amide. There is also elevated risk for metabolic acidosis and 
nephrolithiasis during concomitant use of acetazolamide 
and brinzolamide, dorzolamide, topiramate or zonisamide. 
Travel medicine providers should be also aware of a possi-
ble interaction between acetazolamide and loop diuretics, 
tramadol, oxycodone, codeine or metformin. Side effects 
of acetazolamide include paraesthesia, polyuria, rash and 
dysgeusia [10, 55, 89]. In case of contraindications or intol-
erance to acetazolamide, dexamethasone is a well-studied 
alternative. Contrary to acetazolamide it only conceals the 
symptoms of AMS by reducing the inflammation. Dexameth-
asone should not be used for more than 7 consecutive 
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days due to as the drug may produce Cushingoid effects or 
adrenal suppression. Furthermore, it may have significant 
side effects, e.g. insomnia, unmasking of diabetes, peptic 
ulceration and gastrointestinal bleeding. In recent years, the 
effectiveness of inhaled budesonide has been confirmed for 
the prevention of AMS. The drug exhibits fewer side effects 
compared to dexamethasone [55, 89]. Nifedipine is the first-
line drug for prevention and treatment of HAPE. Side effects 
of this medication include AMS-like symptoms: headache, 
swollen ankles and constipation. Particularly noteworthy are 
significant interactions with drugs metabolised by the cyto-
chrome CYP3A4 [55]. Recent studies have suggested that 
sumatriptan, gabapentin and ibuprofen may be effective 
at preventing high-altitude illness; however, further studies 
should be carried out [55, 89].
CONCLUSIONS
Prolonged life expectancy and improved quality of life 
are associated with an increase in the number of elderly trav-
ellers. Although older patients represent a relatively small 
proportion of international travellers, they demand greater 
attention because of the multimorbidity and polypharmacy 
which are seen in many older people. Ageing has a vari-
able effect on common travel-related illnesses. Pre-travel 
counselling performed by a  provider familiar with travel 
medicine is desirable in the group of elderly travellers and 
is a good opportunity to administer both non travel-related 
and travel-associated vaccines, bearing in mind decreased 
immune response in the elderly. Advanced age also affect 
the management of malaria prevention, travellers’ diarrhoea 
and altitude illness. In light of these findings, every case 
should be considered on an individual basis. 
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